FFA
TRVI icon

Farther Finance Advisors’s Trevi Therapeutics TRVI Stock Holding History

Farther Finance Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172K Sell
9,226
-17
-0.2% -$247 ﹤0.01% 2362
2026
Q1 		$107K Sell
9,243
-27
-0.3% -$302 ﹤0.01% 2464
2025
Q4 		$116K Buy
9,270
+432
+5% +$4.99K ﹤0.01% 2245
2025
Q3 		$80.9K Hold
8,838
– – ﹤0.01% 2164
2025
Q2 		$48.3K Buy
8,838
+8,783
+15,969% +$54.6K ﹤0.01% 2150
2025
Q1 		$331 Hold
55
– – ﹤0.01% 3853
2024
Q4 		$227 Hold
55
– – ﹤0.01% 3630
2024
Q3 		$184 Hold
55
– – ﹤0.01% 3672
2024
Q2 		$159 Hold
55
– – ﹤0.01% 3527
2024
Q1 		$185 Buy
+55
New +$123 ﹤0.01% 3287

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Farther Finance Advisors's TRVI Position: Q2 2026 in Review

Farther Finance Advisors reduced its Trevi Therapeutics (TRVI) stake by 0.18% in Q2 2026, selling an estimated $247 and leaving 9,226 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #2362.

Farther Finance Advisors first reported a position in TRVI in Q1 2024 and has held it in 10 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Farther Finance Advisors held 9,226 shares of Trevi Therapeutics worth $172K as of Q2 2026.
  • Farther Finance Advisors sold 17 Trevi Therapeutics shares in Q2 2026, an estimated $247.
  • Trevi Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #2362 holding.
  • Farther Finance Advisors first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.